DTIL

Over the past six months, Precision BioSciences experienced several stock-impacting events: in March 2026, it received U.S. FDA clearance for an Investigational New Drug (IND) application for PBGENE-DMD and earned a $7.5 million clinical milestone payment from TG Therapeutics for the azer-cel program. In April 2026, the ELIMINATE-B clinical trial expanded into Europe, and the FUNCTION-DMD clinical trial advanced with its first site activation and patient enrollment. On May 5, 2026, the company reported first-quarter 2026 financial results, showing $10.8 million in revenues and narrowed losses. On July 27, 2026, changes to its Senior Leadership Team were announced. In August 2026, analysts downgraded revenue estimates for the year, forecasting a significant decline and increased per-share losses, and the company reported second-quarter 2026 financial results with $0 revenue and a $32.7 million net loss primarily due to warrant liabilities. Dosing commenced in the Phase 1/2 FUNCTION-DMD Study on August 24, 2026, and iECURE presented updated clinical data from the OTC-HOPE Trial of ECUR-506 on August 27, 2026. As of September 14, 2026, the share price was $6.88, marking a 52.89% increase from $4.50 on September 15, 2025, with a 52-week trading range between $3.53 and $9.62.